Summary
- Main use
- Treatment in combination with ADT for newly diagnosed high-risk metastatic hormone-sensitive prostate cancer
- Who takes it
- Adults
- Adult dose
- The recommended dose of this medicine is 2 tablets once daily (abiraterone acetate (micronized) 1,000mg/prednisolone 5mg). Do not take this medicine with food. This medicine must be taken once daily on an empty stomach. Take this medicine at least 2 hours after a meal, and do not eat for at least 1 hour after taking it. Swallow the tablets whole with water. This medicine should be administered to patients for whom concomitant treatment with abiraterone and prednisolone is appropriate. If the dose of this medicine needs to be adjusted because of adverse reactions, switch to abiraterone acetate monotherapy. Recommended monitoring Before starting treatment with this medicine, measure serum aminotransferases and bilirubin every 2 weeks during the first 3 months of treatment and monthly thereafter. Monitor blood pressure, serum potassium, and fluid retention monthly. 1. Dose adjustment in patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. In patients with moderate hepatic impairment (Child-Pugh Class B) who were not cancer patients, systemic exposure to abiraterone increased approximately 3.6-fold after a single dose of 1,000mg of abiraterone acetate. There are no data on the clinical safety and efficacy of multiple-dose abiraterone acetate in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). This medicine should be used with caution in patients with moderate hepatic impairment only when the potential benefit clearly outweighs the potential risk. This medicine must not be used in patients with severe hepatic impairment. If hepatotoxicity (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increased to more than 5 times the upper limit of normal, or bilirubin increased to more than 3 times the upper limit of normal) occurs during treatment with this medicine, withhold treatment until liver function test results return to normal. Once liver function test results have recovered, the patient may be retreated with a reduced dose of abiraterone acetate monotherapy, 500mg once daily. In patients who are retreated, monitor serum aminotransferases and bilirubin at least every 2 weeks during the first 3 months and monthly thereafter. If hepatotoxicity recurs at the reduced dose of abiraterone acetate 500mg once daily, discontinue treatment. The reduced dose must not be taken with food. If severe hepatotoxicity (ALT or AST at 20 times the upper limit of normal) occurs during treatment, discontinue this medicine, and do not retreat the patient with this medicine. 2. Dose adjustment in patients with renal impairment No dose adjustment is required in patients with renal impairment. Patients with prostate cancer and severe renal impairment have not been studied; use caution when administering this medicine.
Ingredients
- Manufacturer
- Hanmi Pharmaceutical Co., Ltd.
Efficacy & effects
Treatment in combination with ADT for newly diagnosed high-risk metastatic hormone-sensitive prostate cancer
View approved original textHide original text
For newly diagnosed patients with hormone-responsive high-risk metastatic prostate cancer (mHSPC), combination therapy with androgen deprivation therapy (ADT) is recommended. This combination therapy blocks the action of male hormones, which play an important role in the growth of cancer cells, thus inhibiting cancer cell proliferation. This helps to slow the progression of the disease and improve survival rates. It is important for patients to take the medication consistently as directed by their doctor to enhance treatment efficacy. Additionally, it is wise to discuss and manage side effects with healthcare professionals during treatment. This therapy effectively improves the progression of prostate cancer.
How to take
Adult dose
The recommended dose of this medicine is 2 tablets once daily (abiraterone acetate (micronized) 1,000mg/prednisolone 5mg). Do not take this medicine with food. This medicine must be taken once daily on an empty stomach. Take this medicine at least 2 hours after a meal, and do not eat for at least 1 hour after taking it. Swallow the tablets whole with water. This medicine should be administered to patients for whom concomitant treatment with abiraterone and prednisolone is appropriate. If the dose of this medicine needs to be adjusted because of adverse reactions, switch to abiraterone acetate monotherapy. Recommended monitoring Before starting treatment with this medicine, measure serum aminotransferases and bilirubin every 2 weeks during the first 3 months of treatment and monthly thereafter. Monitor blood pressure, serum potassium, and fluid retention monthly. 1. Dose adjustment in patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. In patients with moderate hepatic impairment (Child-Pugh Class B) who were not cancer patients, systemic exposure to abiraterone increased approximately 3.6-fold after a single dose of 1,000mg of abiraterone acetate. There are no data on the clinical safety and efficacy of multiple-dose abiraterone acetate in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). This medicine should be used with caution in patients with moderate hepatic impairment only when the potential benefit clearly outweighs the potential risk. This medicine must not be used in patients with severe hepatic impairment. If hepatotoxicity (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increased to more than 5 times the upper limit of normal, or bilirubin increased to more than 3 times the upper limit of normal) occurs during treatment with this medicine, withhold treatment until liver function test results return to normal. Once liver function test results have recovered, the patient may be retreated with a reduced dose of abiraterone acetate monotherapy, 500mg once daily. In patients who are retreated, monitor serum aminotransferases and bilirubin at least every 2 weeks during the first 3 months and monthly thereafter. If hepatotoxicity recurs at the reduced dose of abiraterone acetate 500mg once daily, discontinue treatment. The reduced dose must not be taken with food. If severe hepatotoxicity (ALT or AST at 20 times the upper limit of normal) occurs during treatment, discontinue this medicine, and do not retreat the patient with this medicine. 2. Dose adjustment in patients with renal impairment No dose adjustment is required in patients with renal impairment. Patients with prostate cancer and severe renal impairment have not been studied; use caution when administering this medicine.
Precautions
This drug should not be used by women who are pregnant or may become pregnant. Patients allergic to the ingredients in this medication should also not take it. Co-administration with Radium-223 dichloride can increase mortality and fracture risk, so it should be avoided. Patients with infections or weakened immune function may experience exacerbation of infections and require caution. Patients with severe liver dysfunction should not use this drug, and those with moderate to severe liver function should carefully consider the risks and benefits. Frequent liver function tests should be conducted, and if signs of liver damage occur, the medication should be discontinued. This medication may raise blood pressure, lower potassium levels in the blood, and cause fluid retention, so patients with heart or kidney disease should undergo regular blood pressure and blood tests. Additionally, symptoms of muscle damage such as myopathy or rhabdomyolysis may occur while taking this drug, so patients should consult their doctor if they experience muscle pain or weakness. Taking this drug with food may alter its effectiveness, so it must be taken on an empty stomach, and patients should inform their healthcare provider of any other medications they are taking due to potential interactions. As it contains corticosteroids, there is an increased risk of infections, and live vaccinations are prohibited. Long-term use may lead to side effects such as adrenal insufficiency, osteoporosis, hypertension, and diabetes, necessitating periodic testing. This drug is not intended for children, and caution should be exercised when used in older patients due to a higher risk of side effects. In case of overdose, medication should be stopped immediately, and appropriate treatment, including monitoring for arrhythmias and liver function, should be undertaken. Lastly, this medication should be stored out of reach of children and kept in its original container to maintain quality.
Side effects
Peripheral edema, hypokalemia, increased alanine aminotransferase, increased aspartate aminotransferase, hypertension, urinary tract infection, hypertriglyceridemia, fractures, heart failure, angina, arrhythmia, atrial fibrillation, tachycardia, fatigue, edema, fever, joint swelling, groin pain, constipation, diarrhea, dyspepsia, facial flushing, cough, dyspnea, insomnia, contusion, falls, upper respiratory infection, nasopharyngitis, hematuria, rash, adrenal insufficiency, allergic alveolitis, rhabdomyolysis, myopathy, fulminant hepatitis, acute liver failure, QT prolongation, Torsades de Pointes, anaphylactoid reaction, back pain, limb pain, bone pain, flank pain, spinal osteoarthritis, joint swelling, spinal foraminal stenosis, weakness, facial edema, pain, chest pain, chest discomfort, mucosal inflammation, dizziness, headache, sensory impairment, burning sensation, paresthesia, nausea, vomiting, abdominal pain, esophagitis, enteritis, fecal incontinence, hemorrhoidal bleeding, diabetes mellitus, decreased appetite, hyperlipidemia, frequent urination, nocturia, elevated prostate-specific antigen, weight gain, increased blood sugar, increased alkaline phosphatase, confusion, anxiety, pruritus, sweating, skin lesions, skin peeling, lymphedema, genital pain, Cushingoid features, cardiac disorders, infections, suppressed adrenocorticotropic hormone secretion, secondary adrenal insufficiency, menstrual disorders, Cushing's syndrome, growth suppression in children, impaired glucose tolerance, buffalo hump, peptic ulcer, pancreatitis, diarrhea, nausea, vomiting, stomach ache, heartburn, abdominal distension, thirst, loss of appetite, increased appetite, mental disorders, depression, euphoria, insomnia, headache, dizziness, seizures, increased intracranial pressure, osteoporosis, aseptic necrosis of the femoral and humeral epiphyses, myopathy, vertebral compression fractures, loss of muscle mass, pathological fractures of the ilium, myalgia, arthralgia, joint instability, tumors, exacerbation of tenderness, negative nitrogen balance, steatosis, edema, fluid retention, sodium retention, potassium loss, congestive heart failure, increased blood pressure, hypokalemic alkalosis, increased intraocular pressure, glaucoma, posterior capsule opacification, central serous chorioretinopathy, multiple posterior pigment epithelium dystrophies, retinal disorders, exophthalmos, blurred vision, leukocytosis, thrombosis, myocardial infarction, cerebral infarction, aneurysm, acne, hirsutism, alopecia, pigmentation, petechiae, ecchymosis, subcutaneous hematoma, purpura, urticaria, itching, abnormal sweating, facial erythema, delayed wound healing, thin and fragile skin, fever, fatigue, steroid-induced nephropathy, weight gain, changes in sperm count and motility, pneumonia, sepsis, acute hepatitis due to reactivation of hepatitis B, hypoglycemia, myopathy, rhabdomyolysis
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius to preserve its effectiveness.
Appearance and packaging
Appearance
White, oval, film-coated tablet
Package unit
56 tablets/box [14 tablets/PTPX4]
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
